Trials / Not Yet Recruiting
Not Yet RecruitingNCT07292012
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab - IV | Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8. |
| DRUG | Mirikizumab - SC | SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-07-01
- Completion
- 2029-01-01
- First posted
- 2025-12-18
- Last updated
- 2025-12-18
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT07292012. Inclusion in this directory is not an endorsement.